Kev kho mob TIL (GT101)

GT101 yog kev kho mob hlwb autologous uas ua los ntawm TIL uas tau nthuav dav thiab rov ua dua tshiab los ntawm tus neeg mob tus kheej lub qog. Kev kho mob yog ua los ntawm kev sau cov nqaij mob qog los ntawm cov neeg mob thiab rho tawm TIL. Cov TIL uas tau rho tawm yuav raug nthuav dav siv Grit Bio lub platform tsim khoom StemTexp® thiab muab rov qab rau hauv cov neeg mob kom tawm tsam cov qog.

Thaum xyoo 2024Lub Rooj Sib Tham Txhua Xyoo ntawm Lub Koom Haum Amelikas ntawm Kev Kho Mob Oncology (ASCO),tau tshaj tawm cov ntaub ntawv ntawm 14 tus neeg mob qog nqaij hlav uas koom nrog hauv kev tshawb fawb GT101. Qhov kev sim no tau tsim los nrog qhov kawg tseem ceeb ntawm kev ntsuam xyuas DLT thiab piav qhia txog qhov kev nyab xeeb ntawm GT101 hauv cov neeg mob qog nqaij hlav ntsuas los ntawm qhov tshwm sim ntawm Qib ≥ 3 kev kho mob-teeb meem tshwm sim (TEAEs). Cov ntsiab lus thib ob yog los ntsuam xyuas cov kev ua tau zoo suav nrog kev teb tag nrho (ORR), tus nqi tswj kab mob (DCR), kev ciaj sia tsis muaj kev nce qib (PFS), lub sijhawm teb (DOR), thiab kev ciaj sia tag nrho (OS) raws li RECIST v1.1.

Cov Txiaj Ntsig: Txij li thaum Lub Kaum Ib Hlis 10, 2023, ib pawg neeg mob ntawm 14 tus neeg tau txais kev kho mob nrog hnub nyoog nruab nrab ntawm 46.9 thiab nruab nrab ntawm 2.6 kab ntawm kev kho mob yav dhau los. Tom qab tus qauv FC-raws li lymphodepletion, cov neeg mob tau undergone GT101 infusion ntawm cov koob tshuaj ≥ 5 × 109 hlwb nrog cov koob tshuaj nruab nrab ntawm 3.7 × 1010 hlwb, ua raws li kev tswj hwm IL-2 siab. Feem ntau ntawm cov Qib ≥ 3 AEs pom tau cuam tshuam nrog FC conditioning regimen thiab IL-2, suav nrog cov lej lymphocyte txo qis, cov lej ntshav dawb txo qis, cov lej neutrophil txo qis, anemia, pyrexia thiab cov lej platelet txo qis. Feem ntau ntawm cov AEs no tau zoo rov qab hauv 14 hnub, thaum ob peb tau downgraded rau ≤ Qib 2 hauv 4 lub lis piam. Ntawm 14 tus neeg mob sau npe hla ntau yam cim (mob qog nqaij hlav me me, melanoma, mob qog nqaij hlav caj dab), ORR yog 35.7%. Tshwj xeeb, 4 pts (28.6%) muaj kev teb ib nrab (PR), 1 pt (7.1%) tau txais kev teb tiav (CR), thiab 8 pts (57.1%) muaj kab mob ruaj khov (SD) ua lawv cov lus teb zoo tshaj plaws. Ib pt muaj kev nce qib ntawm kab mob tsis tau lees paub (PD). Qhov tseem ceeb, ntawm 11/14 tus neeg mob uas muaj mob qog nqaij hlav hauv tsev menyuam, ORR yog 45.5% (5/11) nrog 4 pts (36.4%) tau txais PR thiab 1 pt (9.1%) tau txais CR. Kev tswj kab mob tau pom hauv 10/11 pts (90.9%), thiab qhov nruab nrab PFS yog 4.2 lub hlis rau pawg neeg no. Tus neeg mob CR tau raug saib xyuas ntev thiab lub sijhawm ntawm CR thiab PFS (kwv yees los ntawm Kaplan-Meier) yog 24 lub lis piam thiab 36 lub lis piam, raws li. Tom qab txhaj tshuaj GT101, T cell tau nthuav dav heev hauv cov ntshav ntawm txhua tus neeg mob uas muaj Tmax nruab nrab 6.83 hnub thiab nruab nrab 15.9 hnub.

Xaus Lus: Hauv kev tshawb fawb GT101 Theem 1, tsis muaj SAEs thiab DLT cuam tshuam nrog kev kho mob tau pom. Hauv cov neeg mob uas muaj cov qog nqaij hlav loj lossis metastatic uas tau kho ua ntej lawm, GT101 tau pom tias muaj kev nyab xeeb nyob rau hauv cov txheej txheem kho mob ntawm lymphodepletion thiab IL-2 ntau thiab cov ntaub ntawv kho mob zoo, tshwj xeeb tshaj yog hauv mob qog nqaij hlav caj dab, nrog ORR txhawb nqa thiab lub sijhawm teb ntev.

Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.

Xov Tooj: 4008803716

Email：myimmnet@163.com

Cov ntaub ntawv siv los ua piv txwv

1.https://www.grit-bio.com/newsinfo/4620292.html

2.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2548